Emergent BioSolutions Inc.

EBS · NYSE

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders4.3%

Institutions90.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$742.90M	$1.04B	$1.04B	$1.12B	$1.49B	$1.56B	$1.11B	$782.40M	$560.87M	$488.78M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$326.20M	$405.30M	$705.40M	$693.70M	$398.20M	$524.00M	$433.50M	$322.30M	$195.71M	$131.28M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$100.10M	-$108.70M	-$726.40M	-$172.70M	$352.60M	$433.80M	$114.10M	$89.80M	$124.28M	$105.52M
Operating income as a percentage of revenue.	13.5%	-10.4%	-69.6%	-15.5%	23.6%	27.9%	10.3%	11.5%	22.2%	21.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$52.60M	-$190.60M	-$760.50M	-$223.80M	$230.90M	$305.10M	$54.50M	$62.70M	$82.59M	$51.78M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.98	$-3.60	$-14.85	$-4.47	$4.32	$5.79	$1.06	$1.00	$1.00	$1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.93	$-3.60	$-14.85	$-4.47	$4.27	$5.67	$1.04	$1.00	$1.00	$1.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$205.40M	$99.50M	$111.70M	$642.60M	$576.10M	$621.30M	$167.80M	$112.20M	$178.29M	–
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.32B	$1.39B	$1.82B	$3.17B	$2.96B	$2.88B	$2.33B	$2.23B	$1.07B	$970.11M
All of the company's interest-bearing borrowings, short and long term combined.	$572.10M	$663.70M	$860.20M	$1.41B	$841.00M	$874.80M	$811.30M	$794.60M	$13.46M	$268.09M
Everything the company owes — debt, unpaid bills, and other obligations.	$796.00M	$906.90M	$1.17B	$1.78B	$1.34B	$1.44B	$1.24B	$1.22B	$157.86M	$373.91M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$522.60M	$482.80M	$649.30M	$1.38B	$1.62B	$1.45B	$1.09B	$1.01B	$912.35M	$596.21M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$170.60M	$58.70M	-$206.30M	-$34.10M	$321.10M	$536.00M	$188.00M	$41.80M	$208.14M	$53.49M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$13.80M	$22.90M	$51.60M	$115.80M	$225.00M	$141.00M	$86.90M	$72.10M	$54.83M	$76.26M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$156.80M	$35.80M	-$257.90M	-$149.90M	$96.10M	$395.00M	$101.10M	-$30.30M	$153.31M	-$22.77M

	You	Peer avg
P/E	–	15.5
Revenue Growth	+66.3%	-51.0%
ROE	-40.3%	-29.9%

Emergent BioSolutions Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison